Topical silver diamine fluoride for managing dental caries in children and adults by Rajendra, Anjana et al.
                                                                    
University of Dundee
Topical silver diamine fluoride for managing dental caries in children and adults
Rajendra, Anjana; Veitz-Keenan, Analia; Oliveira, Branca Heloisa; Ruff, Ryan R.; Wong, May
C.M.; Innes, Nicola P.T.
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Rajendra, A., Veitz-Keenan, A., Oliveira, B. H., Ruff, R. R., Wong, M. C. M., Innes, N. P. T., Radford, J., Seifo,
N., & Niederman, R. (2017). Topical silver diamine fluoride for managing dental caries in children and adults.
Cochrane Database of Systematic Reviews, 2017(7), [CD012718]. https://doi.org/10.1002/14651858.CD012718
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Sep. 2020
Cochrane Database of Systematic Reviews
Topical silver diamine fluoride for managing dental caries in
children and adults (Protocol)
Rajendra A, Veitz-Keenan A, Oliveira BH, Ruff RR, Wong MCM, Innes NPT, Radford J, Seifo N,
Niederman R
Rajendra A, Veitz-Keenan A, Oliveira BH, Ruff RR, Wong MCM, Innes NPT, Radford J, Seifo N, Niederman R.
Topical silver diamine fluoride for managing dental caries in children and adults.
Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012718.
DOI: 10.1002/14651858.CD012718.
www.cochranelibrary.com
Topical silver diamine fluoride for managing dental caries in children and adults (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iTopical silver diamine fluoride for managing dental caries in children and adults (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Topical silver diamine fluoride for managing dental caries in
children and adults
Anjana Rajendra1, Analia Veitz-Keenan2, Branca Heloisa Oliveira3, Ryan R Ruff1, May CMWong4, Nicola PT Innes5, John Radford
6, Nassar Seifo5, Richard Niederman1
1Epidemiology and Health Promotion, New York University College of Dentistry, New York, USA. 2Department of Oral Maxillofacial
Pathology, Radiology and Medicine, New York University College of Dentistry, New York, USA. 3Faculty of Dentistry, Rio de Janeiro
State University, Rio de Janeiro, Brazil. 4Dental Public Health, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.
5Dundee Dental School, University of Dundee, Dundee, UK. 6Division of Restorative Dental Sciences, Dundee Dental Hospital and
School, Dundee, UK
Contact address: Analia Veitz-Keenan, Department of Oral Maxillofacial Pathology, Radiology and Medicine, New York University
College of Dentistry, 345 East 24th Street, New York, NY 10010, USA. av244@nyu.edu.
Editorial group: Cochrane Oral Health Group.
Publication status and date: New, published in Issue 7, 2017.
Citation: Rajendra A, Veitz-Keenan A, Oliveira BH, Ruff RR, Wong MCM, Innes NPT, Radford J, Seifo N, Niederman R. Topical
silver diamine fluoride for managing dental caries in children and adults. Cochrane Database of Systematic Reviews 2017, Issue 7. Art.
No.: CD012718. DOI: 10.1002/14651858.CD012718.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of silver diamine fluoride in arresting and preventing caries in deciduous and permanent teeth (coronal and root
caries) compared to any other intervention including placebo or no treatment.
B A C K G R O U N D
Description of the condition
Dental caries is the globe’s most prevalent disease (Marcenes 2013;
Kassebaum 2015). Scoping reviews indicate that cost-effective pre-
ventive agents, that canbe applied by families or community health
workers are available, but underused (Niederman 2015). Caries af-
fects farmore than a person’s oral health. The range of associated is-
sueswith untreated caries and toothaches range from reduced qual-
ity of life to poor school performance (Farber 2004; Blumenshine
2008; Seirawan 2012; Detty 2014; PRNewswire July 2015). Poor
oral health is also associated with inhibited growth and devel-
opment, psychosocial vulnerability, lower well-being and self-ef-
ficacy, and reduced locus of control (Quiñonez 2001; Finlayson
2007; Mattheus 2010; Adair 2013; CMS 2013).
Description of the intervention
Early studies in medicine found that silver nitrate is an effective
antimicrobial agent (Von Naegeli 1893). This led to the use of
silver nitrate, silver foil, and silver sutures for the prevention of
ocular and surgical infections (Halstead 1895). These findings led
to the application of silver nitrate to treat caries, creating sclerotic
or calcified dentin formation (Stebbins 1891). The hypothesized
mechanism was a potent germicidal effect combined with the de-
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position of silver phosphate salt (Miller 1905; Howe 1917). Den-
tists termed silver nitrate ’Howe’s solution’ after Percy Howe, who
first systematically reported on its use for caries prevention.
The specific interest in silver diamine fluoride (SDF) centers
around its five presumed attributes (Thibodeau 1978): (1) control
of pain and infection; (2) ease and simplicity of use (paint on); (3)
affordability of material (pennies per application); (4) minimal re-
quirement for personnel time and training (one minute, once per
year); and (5) the fact that it is non-invasive. In this sense, some
authors refer to SDF as a potential agent to disrupt the traditional
approaches to caries prevention and control (Christensen 2009).
In vitro studies suggested that silver fluoride regimens inhibit Strep-
tococcus mutans growth (Thibodeau 1978) and penetrate enamel
to a depth of 25 microns, and that approximately two to three
times more fluoride is retained than that delivered by sodium fluo-
rophosphate (NaF-PO4), sodium fluoride (NaF), or stannous flu-
oride (SnF2) (Suzuki 1974). The in vitro studies suggest that the
effect of SDF may be greater than that of NaF or SnF2.
Early in vivo studies in primary teeth indicated that silver fluoride
applicationmay inhibit the lateral spread of caries (Nishino 1969).
More recent, in vivo studies in permanent teeth indicated that
silver fluoride may arrest approximal caries progression (Battelle
1991). These initial studies led to the use of silver diamine fluoride
in Australia (Gotjamanos 1997), Japan (Yamaga 1969), and Brazil
(Almeida 1994).
It is mentioned in the literature that the most effective, simplest,
and least expensive caries preventive agents are silver nitrate (which
kills the causative bacteria) and fluoride (which renders the teeth
less soluble to bacterial acids) (Niederman 2015). The creation of
a silver nitrate fluoride construct - silver diamine fluoride (SDF) -
combines these two preventive agents (Rosenblatt 2009). SDF is
thought to arrest and prevent decay progression by (1) killing the
causative bacteria, (2) depositing a layer of protective silver phos-
phate that resists further decay, and (3) converting the more acid
soluble hydroxyapatite to the less soluble fluorapatite (Rosenblatt
2009).
How the intervention might work
Multiple modes of action have been proposed for silver diamine
fluorides (Rosenblatt 2009). This may, in part, be explained
by the multiple biological organisms (e.g. bacterial, protozoan,
fungal, and viral), subcellular targets (e.g. cell membranes, or-
ganelles, nuclei), and mechanisms (e.g. metabolism, replication)
that have been examined. Studies indicate that silver interacts with
sulfhydryl groups of proteins and with DNA, altering hydrogen
bonding and inhibiting respiratory processes, DNA unwinding,
cell-wall synthesis, and cell division. At themacro level, these inter-
actions effect bacterial killing and inhibit biofilm formation (Wu
2007). The central mechanism for these diverse effects is proposed
to be the interaction of silver with thiol groups (Russell 1994).
Why it is important to do this review
Several countries such as Japan, China, New Zealand, Australia,
and many South American countries have been using silver di-
amine fluoride for many decades for arresting caries. Silver di-
amine fluoride is available and approved for use in multiple Asian
and South American countries (Niederman 2015).
Recently in 2014 the US Food and Drug Administration (FDA)
approved the use of SDF as a treatment of dentinal hypersensitivity
in patients aged 21 and older, but many people have been using
SDF off-label for the treatment of cavitated lesions, particularly
in children. Several randomised controlled trials are showing that
SDF can be used to halt the progression of caries (Rosenblatt 2009;
Gao 2016).
The expanding availability of SDFandmore than100publications
cited onPubMed suggest the need for anupdated systematic review
examining multiple aspects of silver diamine fluoride’s potential
utility.
Hence, a Cochrane Review of randomised controlled trials to eval-
uate the effectiveness of SDF for caries arrest and prevention will
provide a source of evidence for global decision making.
O B J E C T I V E S
To assess the effects of silver diamine fluoride in arresting and
preventing caries in deciduous and permanent teeth (coronal and
root caries) compared to any other intervention including placebo
or no treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of parallel-group and split-mouth
design comparing the use of silver diamine fluoride with any other
intervention or placebo or no treatment, in patients with any type
of carious lesions andwithout carious lesions. Any length in follow-
up period will be considered for inclusion.
Types of participants
Children, adolescents and adults with any type of carious lesions
or without carious lesions in anterior or posterior deciduous or
permanent teeth or both.
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Types of interventions
Topical applicationof any concentrationor durationof application
of silver diamine fluoride in anterior or posterior deciduous or
permanent teeth with any type of carious lesions or without caries,
treatment performed with or without caries excavation compared
to any other intervention including placebo or no treatment.
Types of outcome measures
Primary outcomes
• Caries prevention, as measured by change from baseline in
the number of decayed missing, filled permanent surfaces
(DMFS), and decayed missing filled primary surfaces (dmfs).
• Caries arrest indicated by change from active to arrested
caries, measured by visual changes in enamel and dentin or any
other ways that may be used for caries arrest evaluation.
Secondary outcomes
• Adverse events (e.g. allergic reactions/taste disturbances,
stains, decreased bond strength for direct restorations).
• Dental pain or sensitivity (e.g. pain and postoperative
sensitivity may be measured by a visual analog scale (VAS), tested
by practitioner or patient self-report).
• Aesthetics (e.g. acceptability of color changes in carious
lesions assessed by patient, parent or clinician).
Search methods for identification of studies
Electronic searches
Cochrane Oral Health’s Information Specialist will conduct sys-
tematic searches for randomised controlled trials and controlled
clinical trials. Due to the Cochrane Embase Project to identify all
clinical trials on the database and add them to CENTRAL, only
recent months of the Embase database will be searched. Please
see the searching page on the Cochrane Oral Health website for
more information. No other restrictions will be placed on the
language or date of publication when searching the electronic
databases.
We will search the following databases for relevant trials:
• Cochrane Oral Health’s Trials Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Register of Studies;
• MEDLINE Ovid (from 1946 onwards);
• Embase Ovid (previous six months to date).
The subject strategies for databases will be modelled on the search
strategy designed for MEDLINE Ovid in Appendix 1.
Searching other resources
The following trials registries will be searched:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (http://clinicaltrials.gov/);
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We will check the bibliographies of included studies and any rele-
vant systematic reviews identified for further references to relevant
trials.
We will not perform a separate search for adverse effects of inter-
ventions used for the treatment. We will consider adverse effects
described in included studies only.
The search will include online abstracts indexes of conference pro-
ceedings if available such as the abstracts from the International
Association for Dental Research (IADR) or the American Associ-
ation of Dental Research (AADR).
Data collection and analysis
Selection of studies
For data collection and analysis two review authors (Anjana Rajen-
dra (AR) and Analia Veitz-Keenan (AVK)) will independently and
in duplicate screen the identified titles and abstracts for possible
inclusion in the review. A third author (Richard Niederman (RN))
will arbitrate disagreements. We will obtain all full-text copies of
all potential eligible articles and they will be further evaluated for
final inclusion in detail by the review authors (AR, AVK and RN).
A PRISMA flowchart will be created to summarise the process,
and excluded studies will be reported.
Data extraction and management
We will create a data extraction form for the review. Four review
authors independently and in duplicate will extract data. A fifth
review author will moderate disagreements. All data extracted and
details of all included studies will be entered in the ’Characteristics
of included studies’ tables using Review Manager 5 (RevMan 5)
software (RevMan 2014).
For each study the following characteristics will be reported.
• Publication details (setting/year).
• Methodology.
• Type of participants.
• Type of intervention.
• Control.
• Outcomes.
• Duration and follow-up.
• Sample size.
• Funding/conflict of interest.
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Assessment of risk of bias in included studies
Two review authors (AR and AVK) will independently and
in duplicate assess the risk of bias for all the included ran-
domised controlled studies by using the criteria suggested by the
Cochrane Handbook for Systematic Reviews of Interventions, Chap-
ter 8 (Higgins 2011). A third review author will act as a moderator
for disagreements.
We will grade each study for risk of bias in the seven key domains
suggested:
1. sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
4. blinding of outcome assessor (detection bias);
5. completeness of outcome data (attrition bias);
6. risk of selective data reporting (reporting bias); and
7. other bias.
An overall judgment of ’Low risk’ of bias for a study will be made
when any plausible bias across all seven domains was unlikely to
have altered the results. An overall judgment of ’Unclear risk’ of
bias for a study will be made when any plausible bias across one
or more of the key domains raises some doubt that it may have
altered the results. An overall judgment of ’High risk’ of bias for a
study will be made when any plausible bias across one or more of
the key domains seriously weakens our confidence in the results
reported in that study.
We will complete ’Risk of bias’ tables for each included study. We
will then generate a ’Risk of bias’ summary graph and figure.
Measures of treatment effect
Caries prevention
For change in DMFT/DMFS from baseline comparing treatment
groups, where studies use the same scale to measure the outcome,
we will use mean values and standard deviations reported in stud-
ies to estimate the mean difference (MD) with 95% confidence
intervals. For studies with different scales, we will express treat-
ment effects as standardized mean differences (SMD) and 95%
confidence intervals.
Caries arrest
Using standard 2 x 2 tables for the number of cavitated teeth
arrested and non-arrested, wewill express the estimate of treatment
effects as odds ratios (OR) and 95% confidence intervals.
Unit of analysis issues
We are anticipating that the trials may randomise participants or
teeth to the interventions. The number of observations in the
analysis should match the number of ’units’ that were randomised.
We will follow the Cochrane Handbook for Systematic Reviews of
Interventions, Chapter 9, Section 9.3 (Higgins 2011) in order to
avoid unit of analysis errors.
Parallel trials will use standard meta-analytic procedures including
standard random-effects models of pooled ORs and SMDs.
Analysis of data from split-mouth designs, where available, will
be similar to that for cross-over trials (Cochrane Handbook for
Systematic Reviews of Interventions, Section 16.4 (Higgins 2011)).
For continuous outcomes, analysis will use effect estimates from
paired t-tests and included in meta-analyses using the generic in-
verse variance method. For studies in which relevant information
is not available to incorporate the published data into a meta-
analysis, we will approximate paired analyses by imputing stan-
dard deviations. Specifically, we will consider borrowing standard
deviation differences from similar studies. Alternatively, we will
calculate standard deviation differences using a range of plausible
correlation coefficients (see Sensitivity analysis). For dichotomous
data we will calculate ORs for differences between groups about
whether caries was arrested, along with appropriate standard errors
and 95% confidence intervals, using RevMan 5 (RevMan 2014).
For split-mouth studies, we will calculate ORs using the Becker-
Balagtas method (BB OR) outlined in Curtin 2002 by R soft-
ware Version 3.3.1 (R for Windows 3.3.1). We have chosen this
method because we intend to pool data from split-mouth and par-
allel-group studies in the same meta-analyses, and this method is
appropriate (as outlined by Stedman 2011). If an included study
presented paired data by tooth pairs, we will calculate the intra-
cluster correlation coefficient (ICC) (required for BB OR calcula-
tions) from paired data. If a split-mouth study presents data only
in marginals (as parallel-group studies, not as 2 x 2 cross-classifi-
cation for paired data), we will use the conservative ICC 0.05.
Dealing with missing data
Wewill contact authors of the selected studies for unclear method-
ology, missing or unclear information and missing data. For the
analysis we will include only the available data. We will follow the
methods suggested by Section 7.7.3 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
Clinical heterogeneity will be assessed to examine the type of par-
ticipants, interventions and outcomes of each study.
We will assess heterogeneity by inspection of the point estimates
and confidence intervals on the forest plots. The lack of overlap
of confidence intervals may indicate heterogeneity.
Statistically heterogeneity will be assessed using Cochran’s test for
heterogeneity and the I2 statistic. For the interpretation of statisti-
cal heterogeneity we will use themethods outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
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We will follow the guide to the interpretation of the I2 statistic
given in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011):
• 0% to 40% might not be important;
• 30% to 60% may represent moderate heterogeneity;
• 50% to 90% may represent substantial heterogeneity;
• 75% to 100% considerable heterogeneity.
For the Cochran’s test for heterogeneity we will consider hetero-
geneity for P values < 0.1.
Assessment of reporting biases
If there are more than 10 studies included in the meta-analysis,
we will test for reporting bias by testing for asymmetry in a funnel
plot. If reporting biases are identified, we will carry out analysis
as outlined by Egger 1997 for continuous outcomes and Rucker
2008 for dichotomous outcomes.
Data synthesis
Meta-analysis will be conducted using RevMan 5 software for
studies with similar comparisons and reporting the same outcome
measures. We will combine ORs for dichotomous data (caries
arrest) and mean differences (caries prevention) for continuous
data using random-effects models.
Outcomes from studies with different scales will be converted
to standardized mean differences for continuous outcomes and
overall effects will be re-scaled to a common outcome type.
We will perform meta-analysis if appropriate in order to obtain a
pooled relative risk (OR) for dichotomous outcomes, mean differ-
ences and standardized mean differences (SMD) for continuous
outcomes to assess the effect of topical silver diamine fluoride in
control of dental caries.
Subgroup analysis and investigation of heterogeneity
As described above, subgroup analysis will be considered for any
outcome with an estimated I2 of 40% to 60%, considered as pos-
sible moderate heterogeneity according to the Cochrane Hand-
book for Systematic Reviews of Interventions, Section 9.5.2 (Higgins
2011). However, prior to any subgroup analyses we will consider
both magnitude and direction of effects and strength of the evi-
dence for heterogeneity, via confidence intervals for the I2 statistic.
Subgroup analysis will be performed for study design and by pre-
dominant age group in the study.
Sensitivity analysis
Provided there are sufficient included trials we will conduct sensi-
tivity analysis to evaluate the impact of the following factors:
• studies of high and unclear risk of bias;
• for split-mouth designs, sensitivity analyses will be
conducted to assess the impact of variation in imputed
correlations for the calculation of standard deviations of
differences and odds ratios.
Presentation of main results
The primary and secondary outcomes will be included in ’Sum-
mary of findings’ tables using GRADEpro software (GRADEpro
GDT 2014). We will assess the quality of the body of evidence
with reference to the overall risk of bias of the included studies,
inconsistency and directness of the evidence, the precision of the
estimates, and the publications bias.
We will categorize the quality of the body of evidence for each
outcome as high, moderate, low and very low.
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A P P E N D I C E S
Appendix 1. MEDLINE Ovid search strategy
1. exp Tooth demineralization/
2. (teeth adj5 (cavit$ or caries or carious or decay$ or lesion$ or deminerali$ or reminerali$)).mp.
3. (tooth adj5 (cavit$ or caries or carious or decay$ or lesion$ or deminerali$ or reminerali$)).mp.
4. (dental adj5 (cavit$ or caries or carious or decay$ or lesion$ or deminerali$ or reminerali$)).mp.
5. (enamel adj5 (cavit$ or caries or carious or decay$ or lesion$ or deminerali$ or reminerali$)).mp.
6. (dentin adj5 (cavit$ or caries or carious or decay$ or lesion$ or deminerali$ or reminerali$)).mp.
7. (root adj5 (cavit$ or caries or carious or decay$ or lesion$ or deminerali$ or reminerali$)).mp.
8. Dental plaque/
9. ((dental or tooth or teeth) and plaque).mp.
10. or/1-9
11. (silver adj3 fluorid$).mp.
12. (“silver diamine” or “diamine silver” or “silver diammine” or “diammine silver”).mp.
13. ((silver adj nitrate) or (silver adj3 protein$) or (nano adj3 silver)).mp.
14. ((ammonical or ammoniacal) adj2 silver).mp.
15. (SDF or AgF or AgNO3 or Ag-nano).ti,ab.
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16. (“Advantage Arrest” or “Howe?s Solution” or “Riva Star” or Cariestop or Ancarie or “Salfluoraide di Walter” or (Cariostatic adj4
Inodon) or Saforide or Flurophat or Fagamin or Bioride).mp.
17. or/11-16
18. 10 and 17
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